信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

休市中 12-20 16:00:00 EST

3.35

-0.10

-2.90%

盘后3.35

+0.000.00%

16:30 EST

最高3.50	最低3.33	成交量24.51万
今开3.41	昨收3.45	日振幅4.93%
总市值1.64亿	流通市值1.19亿	总股本4,907万
成交额82.93万	换手率0.69%	流通股本3,548万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":3.35,"timestamp":1734728400000,"preClose":3.45,"halted":0,"volume":245137,"hourTrading":{"tag":"盘后","latestPrice":3.35,"preClose":3.35,"latestTime":"16:30 EST","volume":19338,"amount":64781.74,"timestamp":1734730244009},"delay":0,"floatShares":35478989,"shares":49072315,"eps":-0.066318,"marketStatus":"休市中","marketStatusCode":7,"change":-0.1,"latestTime":"12-20 16:00:00 EST","open":3.41,"high":3.5,"low":3.33,"amount":829290.430506,"amplitude":0.049275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.066318,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1171256400000,"adjPreClose":3.45,"adrRate":0,"dividendRate":0.053731,"preHourTrading":{"tag":"盘前","latestPrice":3.5,"preClose":3.45,"latestTime":"09:08 EST","volume":5,"amount":17.5,"timestamp":1734703697752},"postHourTrading":{"tag":"盘后","latestPrice":3.35,"preClose":3.35,"latestTime":"16:30 EST","volume":19338,"amount":64781.74,"timestamp":1734730244009},"volumeRatio":2.7641314753276736,"impliedVol":1.0628,"impliedVolPercentile":0.7222},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2493725422","title":"Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2493725422","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493725422?lang=zh_cn&edition=full","pubTime":"2024-12-21 02:13","pubTimestamp":1734718380,"startTime":"0","endTime":"0","summary":"试验未显示出 uproleselan 具有良好的疗效。Uproleselan 治疗组的严重不良事件发生率为 43%，单纯化疗组为 39%。Uproleselan 治疗组最常见的严重不良事件是血小板数量减少、感染性肺炎和败血症。2024 年 8 月，Apollomics 宣布减记与 uproleselan 项目预付款相关的无形资产。Apollomics 即将完成临床试验，预计 uproleselan 项目的未来费用将低于 50 万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/20/3000788/0/zh-hans/Apollomics-%E5%85%AC%E5%B8%83%E5%9C%A8%E4%B8%AD%E5%9B%BD%E5%AF%B9%E5%A4%8D%E5%8F%91%E6%88%96%E9%9A%BE%E6%B2%BB%E6%80%A7%E6%80%A5%E6%80%A7%E9%AB%93%E7%B3%BB%E7%99%BD%E8%A1%80%E7%97%85%E6%82%A3%E8%80%85%E8%BF%9B%E8%A1%8C%E7%9A%84-Uproleselan-III-%E6%9C%9F%E6%A1%A5%E6%8E%A5%E8%AF%95%E9%AA%8C%E4%B8%BB%E8%A6%81%E7%BB%93%E6%9E%9C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","APLMW","III"],"gpt_icon":0},{"id":"2492419234","title":"G-III服装集团盘中异动 股价大跌5.26%报31.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492419234","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492419234?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:31","pubTimestamp":1734705076,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日22时31分，G-III服装集团股票出现波动，股价大幅下跌5.26%。截至发稿，该股报31.90美元/股，成交量7.8036万股，换手率0.18%，振幅1.81%。G-III服装集团股票所在的服装制造行业中，整体跌幅为0.16%。G-III服装集团公司简介：G-III Apparel Group Ltd 是一家纺织公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122022311795ea9c14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122022311795ea9c14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["III","BK4202","BK4134","GIII"],"gpt_icon":0},{"id":"2492259413","title":"康希诺生物(06185)：青少年及成人用Tdcp疫苗启动II/III期临床试验并完成II期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492259413","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492259413?lang=zh_cn&edition=full","pubTime":"2024-12-20 18:54","pubTimestamp":1734692053,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司开发的吸附无细胞百(组分)白破联合疫苗于近日正式启动II/III期临床试验，并完成II期临床试验首例受试者入组。青少年及成人用Tdcp疫苗适用于6岁及以上人群，为青少年及成人的百白破加强疫苗。尽管主要发达国家已将该疫苗纳入常规的疫苗接种计划，但目前国内并无获批的青少年及成人用百白破加强疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1515","BK1583","06185","BK1161","03347","BK1576","BK1141","BK1574","III","BK1191","159646"],"gpt_icon":0},{"id":"2492944491","title":"国家互联网信息办公室关于发布第九批深度合成服务算法备案信息的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2492944491","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492944491?lang=zh_cn&edition=full","pubTime":"2024-12-20 17:14","pubTimestamp":1734686061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0878005551.USD","BK1502","SG9999002463.SGD","SG9999017495.SGD","LU0871576103.HKD","160636","159792","III","LU1961090484.USD","LU0605514214.HKD","LU1226287792.SGD","LU0821914370.USD","LU0455707207.USD","BK4585","SG9999014914.USD","SG9999002828.SGD","LU0235996351.USD","LU0315178854.USD","LU0320764599.SGD","LU1951186391.HKD","LU2097828714.EUR","LU0501845795.SGD","01357","IE00B5MMRT66.SGD","00700","LU0868486357.SGD","LU1504937902.USD","LU0862451753.SGD","TCEHY","IE0034224299.USD","SGXZ90724238.SGD","LU2317271919.USD","LU0823426308.USD","LU1048596156.SGD","LU0431992006.USD","SG9999001226.SGD","LU0307460666.USD","HTCD.SI","LU0047713382.USD","BK1095","LU0326950275.SGD","LU0345775950.USD","LU0594300419.USD","LU1044874839.SGD","LU2097828631.EUR","80700","LU2152927971.USD","IE00BPRC5H50.USD","LU0348825331.USD","LU1323998911.USD"],"gpt_icon":0},{"id":"2492195096","title":"墨西哥2024年玉米产量料为10多年来最低","url":"https://stock-news.laohu8.com/highlight/detail?id=2492195096","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492195096?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:24","pubTimestamp":1734575069,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["BK4134","ZCmain","III"],"gpt_icon":0},{"id":"2492901547","title":"中国生物制药创新药III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901547","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901547?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:01","pubTimestamp":1734519698,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412183272216750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272216750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","III","BK4134","06978","01177","BK1191","BK1515","BK1574","BK1589","BK1521"],"gpt_icon":0},{"id":"2492972512","title":"中国生物制药(01177)：贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊用于非小细胞肺癌放化疗后巩固治疗III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492972512","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492972512?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:04","pubTimestamp":1734512647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊作为巩固治疗在同步╱序贯放化疗后未进展的、局部晚期╱不可切除的非小细胞肺癌患者中的III期临床研究 已完成方案预设的期中分析，独立数据监查委员会判定主要研究终点无进展生存期达到方案预设的优效界值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1191","BK1521","III","BK1515","01177","BK1589"],"gpt_icon":0},{"id":"2491932899","title":"工信部：巩固信息通信业竞争优势和领先地位，实施“5G+工业互联网”升级行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2491932899","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491932899?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:50","pubTimestamp":1734087024,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4134","161631","III","160636","159792","399258"],"gpt_icon":0},{"id":"2490808284","title":"董宇辉近期成立3家新公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2490808284","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490808284?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:15","pubTimestamp":1733998502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["160636","159792","III","BK4134"],"gpt_icon":0},{"id":"2490434690","title":"高盛(GS.N)CEO：重要的是要找到一条合适的途径，在明年敲定巴塞尔协议III的规则。","url":"https://stock-news.laohu8.com/highlight/detail?id=2490434690","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490434690?lang=zh_cn&edition=full","pubTime":"2024-12-11 00:46","pubTimestamp":1733849199,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4516","III","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2237443895.HKD","LU2237443382.USD","BK4533","IE00BFXG1179.USD","BK4127","IE0034235188.USD","IE0002270589.USD","BK4504","LU1668664300.SGD","BK4588","BK4550","BK4134","BK4585","LU2237443465.HKD","LU2237443978.SGD","LU2237443622.USD","BK4552","IE0004091025.USD","LU0106831901.USD","IE0004086264.USD","IE00B19Z3581.USD","LU1791807156.HKD","LU2237438978.USD","LU2237443549.SGD"],"gpt_icon":0},{"id":"2490518019","title":"G-III服装集团盘中异动 大幅跳水5.79%报29.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490518019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490518019?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841078,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，G-III服装集团股票出现波动，股价快速跳水5.79%。截至发稿，该股报29.75美元/股，成交量8820股，换手率0.02%，振幅1.39%。G-III服装集团股票所在的服装制造行业中，整体涨幅为0.00%。其相关个股中，即亮集团、思宏国际、威富集团涨幅较大，金铉集团、即亮集团、文斯控股较为活跃，换手率分别为0.79%、0.18%、0.05%，振幅较大的相关个股有即亮集团、文斯控股、G-III服装集团，振幅分别为7.90%、5.26%、2.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223118984b0bb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223118984b0bb0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","III","GIII","BK4202"],"gpt_icon":0},{"id":"1103667772","title":"G-III 服饰2025年前景更新：预计净销售额为31.5亿美元（此前为32亿美元），而预期为32亿美元，调整后每股收益为4.10至4.20美元（此前为3.95至4.05美元），预期为4.02美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=1103667772","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103667772?lang=zh_cn&edition=full","pubTime":"2024-12-10 20:08","pubTimestamp":1733832526,"startTime":"0","endTime":"0","summary":"预计净销售额将增长约2%，达到约31.5亿美元，相比2024财年的净销售额为31亿美元。预计净收入将在1.85亿美元至1.90亿美元之间，或每股摊薄收益在4.08美元至4.18美元之间。相比之下，2024财年的净收入为1.762亿美元，或每股摊薄收益为3.75美元。预计净利息费用约为2040万美元，包括与赎回票据相关的160万美元的非GAAP费用。我们估计2025财年的税率为28.6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GIII","III"],"gpt_icon":0},{"id":"1142991966","title":"G-III服装集团2025年第三季度调整后每股收益$2.59，超出预测值$2.27，销售额$10.86亿低于预测值$10.98亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142991966","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142991966?lang=zh_cn&edition=full","pubTime":"2024-12-10 20:03","pubTimestamp":1733832201,"startTime":"0","endTime":"0","summary":"G-III服装集团公布季度每股收益为$2.59，高于分析师一致预期的$2.27，高出14.1%。相比去年同期的每股收益$2.78，下降了6.83%。公司报告的季度销售额为$10.86亿，低于分析师一致预期的$10.98亿，低了1.06%。相比去年同期的销售额$10.67亿，增长了1.78%。以上内容来自Benzinga Earnings专栏，原文如下：$G-III Apparel Group$  reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.27 by 14.1 percent. This is a 6.83 percent decrease over earnings of $2.78 per share from the same period last year.  The company reported quarterly sales of $1.086 billion which missed the analyst consens","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","GIII"],"gpt_icon":0},{"id":"2490686220","title":"上海：建立并购标的发现和储备机制 聚焦三大先导产业及重点发展的产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2490686220","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490686220?lang=zh_cn&edition=full","pubTime":"2024-12-10 15:15","pubTimestamp":1733814929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399417","159546","BK4134","III","000097.SH","399258","161726","159638","161028","399441","159875","160640","161123","399941","161631","000941.SH"],"gpt_icon":0},{"id":"2490805084","title":"默沙东PD-1抑制剂可瑞达在华获批局部晚期宫颈癌治疗适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2490805084","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490805084?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:57","pubTimestamp":1733813845,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1057294990.SGD","LU0234572021.USD","IE00B1BXHZ80.USD","SG9999002232.USD","LU0122379950.USD","LU1037948541.HKD","LU1989771016.USD","03347","III","LU2361045086.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1066051498.USD","LU0265550946.USD","SG9999001176.SGD","LU2023250843.SGD","BK4533","SG9999001440.SGD","LU0070302665.USD","BK4134","BK4588","LU2361044865.SGD","MRK","BK4139","IE00B2B36J28.USD","LU2468319806.SGD","LU1989772923.USD","LU2106854487.HKD","LU0965508806.USD","IVA","IE00B4R5TH58.HKD","LU1116320901.HKD","LU1934455277.USD","LU1989772840.SGD","SG9999014559.SGD","LU1430594728.SGD","SG9999002224.SGD","LU0203345920.USD","BK1583","LU1093756325.SGD","LU1941712264.USD","LU1983299246.USD","PD","LU0265550359.USD","BK1141","SG9999014567.USD","LU0861579265.USD","LU2461242641.AUD","LU0289739699.SGD","LU1066051811.HKD"],"gpt_icon":0},{"id":"2489211283","title":"微芯生物(688321.SH)披露西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489211283","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489211283?lang=zh_cn&edition=full","pubTime":"2024-12-06 19:34","pubTimestamp":1733484862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 发布公告，西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析，独立评审委员会评估结果显示：在经过广泛抗肿瘤免疫治疗后的总体人群中，西奥罗尼组与安慰剂组相比中位无进展生存期显著延长，降低疾病进展风险70%以上。西奥罗尼单药治疗三线及以上小细胞肺癌III期临床涉及的相关开发支出全额计提资产减值准备，相应减少公司2024年度利润总额8,847.59万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","03347","BK1583","BK4134","688321","III","BK1141","BK0239"],"gpt_icon":0},{"id":"2488152547","title":"商务部：1-10月我国服务进出口总额61255.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488152547","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488152547?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:16","pubTimestamp":1733303782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["III","BK4134","159998"],"gpt_icon":0},{"id":"2488896896","title":"港股异动 | 欧康维视生物-B(01477)午后涨超4% OT-301 III期临床试验Denali试验完成全球患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2488896896","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488896896?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:37","pubTimestamp":1733207879,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，欧康维视生物-B午后涨超4%，截至发稿，涨3.69%，报5.34港元，成交额578.3万港元。消息面上，欧康维视生物发布公告，集团的主要候选药物之一OT -301与集团共同开发，是同类首创的一氧化氮供体型贝美前列素类似物)已于近期在中国完成其第二项III期临床试验逾140名患者的入组。Denali试验包括一项长期安全性扩展试验，已在美国及中国约90个临床点完成逾670名患者的入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1141","01477","BK1574","III","BK1191","BK4134","03347","BK1576"],"gpt_icon":0},{"id":"2488987068","title":"欧康维视生物-B(01477)：OT-301于中国的第二项III期临床试验患者入组已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2488987068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488987068?lang=zh_cn&edition=full","pubTime":"2024-12-03 07:32","pubTimestamp":1733182360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，集团的主要候选药物之一 O T -301 与集团共同开发，是同类首创的一氧化氮供体型贝美前列素类似物)已于近期在中国完成其第二项III期临床试验逾140名患者的入组。Denali试验包括一项长期安全性扩展试验，已在美国及中国约90个临床点完成逾670名患者的入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","BK1576","01477","BK1191","BK1583","BK1141","BK1574","03347"],"gpt_icon":0},{"id":"2488030516","title":"G-III服装集团盘中异动 早盘大幅上涨5.10%报31.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488030516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488030516?lang=zh_cn&edition=full","pubTime":"2024-12-03 00:08","pubTimestamp":1733155716,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日00时08分，G-III服装集团股票出现波动，股价急速上涨5.10%。截至发稿，该股报31.14美元/股，成交量10.9847万股，换手率0.25%，振幅4.42%。G-III服装集团股票所在的服装制造行业中，整体涨幅为0.84%。其相关个股中，G-III服装集团、思宏国际、李维斯涨幅较大，儿童之家、安德玛-A、Pvh Corp.较为活跃，换手率分别为0.77%、0.48%、0.40%，振幅较大的相关个股有思宏国际、即亮集团、儿童之家，振幅分别为8.85%、8.46%、5.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120300083698e4ef35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120300083698e4ef35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GIII","BK4202","BK4134","III"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0771},{"period":"1month","weight":0.0308},{"period":"3month","weight":0.0568},{"period":"6month","weight":0.113},{"period":"1year","weight":-0.2932},{"period":"ytd","weight":-0.2887}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是900多家客户值得信赖的商业合作伙伴，其中包括市场排名前100的企业中的75家以上。ISG致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032374},{"month":2,"riseRate":0.5,"avgChangeRate":0.01232},{"month":3,"riseRate":0.294118,"avgChangeRate":0.031251},{"month":4,"riseRate":0.470588,"avgChangeRate":-0.008187},{"month":5,"riseRate":0.294118,"avgChangeRate":-0.042992},{"month":6,"riseRate":0.470588,"avgChangeRate":0.01535},{"month":7,"riseRate":0.470588,"avgChangeRate":0.021115},{"month":8,"riseRate":0.529412,"avgChangeRate":-0.00064},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.011058},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.036309},{"month":11,"riseRate":0.647059,"avgChangeRate":0.057949},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.00076}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}